Titration of insulin glargine in patients with type 2 diabetes mellitus in Asia: Physician-versus patient-led? Rationale of the Asian treat to target Lantus Study (ATLAS)

Diabetes Technology and Therapeutics

Volumn 13, Issue 1, 2011, Pages 67-72

  Odawara, Masato ^a   Misra, Anoop ^b   Shestakova, Marina ^c   Pan, Chang Yu ^d   Jabbar, Abdul ^e   Freemantle, Nick ^f   Admane, Karim ^g  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Fortis Hospitals   (India)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; ASIA; CLINICAL EFFECTIVENESS; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALGORITHMS; ASIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MIDDLE AGED; PATIENT SATISFACTION; PHYSICIANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RUSSIA;

EID: 78650611353     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0170     Document Type: Article

References (20)

1. China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-1101.
2. Shaw J, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
3. Chan J CN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-2140.
4. Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S9-S30.
5. Chan J CN, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SRG, Hancu N Ilkova H, Ramachandran A, Aschner P: Multifaceted determinants for achieving glycemic control: The International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009;32:227-233.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
7. Philips LS, Branch WT Jr, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical inertia. Ann Intern Med 2001;135:825-834.
8. Kabadi UM: Starting insulin in type 2 diabetes: Overcoming barriers to insulin therapy. Int J Diabetes Dev Ctries 2008;28:65-68.
9. Peyrot M., Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L: Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
10. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288.
11. Bradley C: The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994:111-132.
12. Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska D, Schabmann A, Bradley C: Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: Assessment of improvements in treatment satisfaction with a new insulin analogue. Qual Life Res 2000;9:915-930.
13. The EuroQol Group: EuroQol-a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
14. Ramachandran A, Ma RCW, Snehalatha C: Diabetes in Asia. Lancet 2010;375:408-418.
15. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885.
16. Kikuchi K, Nezu U, Shirakawa J, Sato K, Togashi Y, Kikuchi T, Aoki K, Ito Y, Kimura M, Terauchi Y: Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: Variations with levels of HbA1c. Endocr J 2010;57: 259-266.
17. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:1073-1084.
18. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
19. McMahon GT, Dluhy RG: Intention to treat-initiating insulin and the 4-T Study. N Engl J Med 2007;357:1759-1761.
20. Buse J, Wolffenbuttel BHR, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA: The DURABLE Trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-1013.